Cargando…
LAG3-PD-1 Combo Overcome the Disadvantage of Drug Resistance
Although PD-1 blockade therapy has been promising in cancer treatment, only 4% (pancreatic cancer) to 70% (melanoma) of patients have a positive response to this blockade therapy, which is one of its important disadvantages. Therefore, it is important to seek out new targets for cancer immunotherapy...
Autores principales: | Wei, Yiming, Li, Zhaoming |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9048820/ https://www.ncbi.nlm.nih.gov/pubmed/35494015 http://dx.doi.org/10.3389/fonc.2022.831407 |
Ejemplares similares
-
Targeting Tim-3 in Cancer With Resistance to PD-1/PD-L1 Blockade
por: Tian, Tian, et al.
Publicado: (2021) -
Overcoming resistance to PD-1/PD-L1 inhibitors in esophageal cancer
por: Cheng, Chao, et al.
Publicado: (2022) -
PD-1 and LAG-3 expression in EBV-associated pediatric Hodgkin lymphoma has influence on survival
por: Jimenez, Oscar, et al.
Publicado: (2022) -
Overcoming the LAG3 phase problem
por: Petersen, Jan, et al.
Publicado: (2022) -
Combo Prospecting
por: Hughes, Tony
Publicado: (2018)